An integrated radiolabelled study to determine the mass balance, metabolite profile and identification, and absolute bioavailability of nolasiban in healthy female subjects

Nolasiban is an orally active oxytocin receptor antagonist under development by ObsEva S.A to enhance the receptivity of the endometrium to embryo implantation. As part of the development program an open-labelled, two-part radiolabelled study was performed in female subjects. The study assessed the absorption and disposition of nolasiban after oral and intravenous (IV) administrations and enabled the determination of mass balance, routes and rates of excretion and metabolism, and absolute bioavailability.